Mark Stead | AI, RNA Biology, and the Future of Drug Discovery
Mark Stead joins Executive Insights for Life Sciences Innovators to discuss artificial intelligence, RNA biology, structural biology, and the next generation of therapeutic discovery platforms.
Prefer audio only? Listen to this episode on Spotify.
Episode Overview
In this episode, Mark Stead discusses how Atomic AI is using artificial intelligence and structural biology to model RNA structures with unprecedented accuracy. The conversation explores the therapeutic potential of RNA, the role of AI in drug discovery, and how emerging technologies may enable new treatments across oncology, rare diseases, and other areas of unmet medical need.
Key Themes
- Artificial intelligence in drug discovery
- RNA structure prediction and therapeutic development
- Structural biology and next-generation medicines
- Discovery platforms for oncology and rare diseases
- The intersection of AI and life sciences innovation
- Building scalable biotechnology platforms
Why This Matters for Life Sciences Leaders
As artificial intelligence continues to reshape life sciences, organizations are exploring how advanced computational tools can accelerate discovery, reduce development risk, and unlock new therapeutic opportunities. The conversation highlights the growing importance of RNA biology, platform innovation, and the strategic decisions required to translate emerging technologies into meaningful patient impact.
Guest Link
More from Executive Insights
Explore more conversations with life sciences founders, CEOs, investors, and operators on the Executive Insights for Life Sciences Innovators podcast.
